Literature DB >> 1911150

Kidney biopsy prior to cyclophosphamide therapy in primary nephrotic syndrome.

T K Mattoo1.   

Abstract

The study includes 30 children, 10 each with minimal change nephropathy (MCNS), diffuse mesangial proliferative glomerulonephritis (MesPGN) and focal segmental glomerulosclerosis (FSGS). Indications for kidney biopsy were: steroid resistance in 12 cases, and frequent relapses on maintenance steroid therapy in 18 cases. A 2-year remission was achieved by cyclophosphamide therapy in 6 patients with FSGS, 8 patients with MCNS and 8 patients with MesPGN. In terms of initial response to corticosteroids, only 3 of 8 patients with early steroid resistance responded to cyclophosphamide therapy compared with 3 of 4 with late steroid resistance and 16 of 18 with frequent relapses on maintenance steroid therapy. Response to cyclophosphamide therapy correlates better with the initial corticosteroid response than renal histopathology. A kidney biopsy prior to administration of cyclophosphamide is not essential in patients who respond to initial corticosteroid therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911150     DOI: 10.1007/bf00856654

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  12 in total

1.  Morphological transition in minimal change nephrotic syndrome.

Authors:  A Tejani
Journal:  Nephron       Date:  1985       Impact factor: 2.847

2.  Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns.

Authors:  S L Schulman; B A Kaiser; M S Polinsky; R Srinivasan; H J Baluarte
Journal:  J Pediatr       Date:  1988-12       Impact factor: 4.406

Review 3.  Glomerular disease.

Authors:  S Rosen; E Galvanek; M Levy; R Habib
Journal:  Hum Pathol       Date:  1981-11       Impact factor: 3.466

4.  Evolution of mesangial IgM nephropathy into focal segmental glomerulosclerosis.

Authors:  J C Jennette
Journal:  Am J Nephrol       Date:  1981       Impact factor: 3.754

Review 5.  The primary nephrotic syndrome of childhood. Classification and clinicopathologic study of 406 cases.

Authors:  R Habib; C Kleinknecht
Journal:  Pathol Annu       Date:  1971

6.  Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment.

Authors:  N J Siegel; K M Gaudio; L S Krassner; B M McDonald; F P Anderson; M Kashgarian
Journal:  Kidney Int       Date:  1981-03       Impact factor: 10.612

7.  Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children.

Authors:  J Churg; R Habib; R H White
Journal:  Lancet       Date:  1970-06-20       Impact factor: 79.321

8.  Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood.

Authors:  T M Barratt; A Bercowsky; S G Osofsky; J F Soothill
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

9.  Steroid-responsive nephrotic syndrome of childhood: a long-term study of clinical course, histopathology, efficacy of cyclophosphamide therapy, and effects on growth.

Authors:  J S Berns; K M Gaudio; L S Krassner; F P Anderson; D Durante; B M McDonald; N J Siegel
Journal:  Am J Kidney Dis       Date:  1987-02       Impact factor: 8.860

10.  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

View more
  1 in total

1.  Long-term follow-up after cyclophosphamide therapy in steroid-dependent nephrotic syndrome.

Authors:  Alberto Zagury; Anne Louise de Oliveira; Carlos Augusto Pinheiro de Moraes; Jose Augusto de Araujo Montalvão; Regina Helena Leite Lemos Novaes; Vinicius Martins de Sá; Deise De Boni Monteiro de Carvalho; Tereza Matuck
Journal:  Pediatr Nephrol       Date:  2011-03-13       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.